127 related articles for article (PubMed ID: 11923505)
1. Tackling cancer at the telomeres.
Marx J
Science; 2002 Mar; 295(5564):2350. PubMed ID: 11923505
[No Abstract] [Full Text] [Related]
2. Targeting telomeres and telomerase.
De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
[TBL] [Abstract][Full Text] [Related]
3. Telomerase inhibitors in cancer therapy: current status and future directions.
Incles CM; Schultes CM; Neidle S
Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
[TBL] [Abstract][Full Text] [Related]
4. Telomeres and telomerase as targets for anticancer drug development.
Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC
Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501
[TBL] [Abstract][Full Text] [Related]
5. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
Seimiya H; Muramatsu Y; Ohishi T; Tsuruo T
Cancer Cell; 2005 Jan; 7(1):25-37. PubMed ID: 15652747
[TBL] [Abstract][Full Text] [Related]
6. Telomere biology of pediatric cancer.
Tabori U; Dome JS
Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
[TBL] [Abstract][Full Text] [Related]
7. Telomeres and telomerase: understanding basic structure and potential new therapeutic strategies targeting it in the treatment of cancer.
Sekhri K
J Postgrad Med; 2014; 60(3):303-8. PubMed ID: 25121374
[TBL] [Abstract][Full Text] [Related]
8. Telomeres and telomerase as targets for cancer therapy.
Zimmermann S; Martens UM
Cell Mol Life Sci; 2007 Apr; 64(7-8):906-21. PubMed ID: 17310277
[TBL] [Abstract][Full Text] [Related]
9. Telomerase inhibition, oligonucleotides, and clinical trials.
Corey DR
Oncogene; 2002 Jan; 21(4):631-7. PubMed ID: 11850789
[TBL] [Abstract][Full Text] [Related]
10. Telomeres and telomerase: Biological and clinical importance in dogs.
Nasir L
Vet J; 2008 Feb; 175(2):155-63. PubMed ID: 17398127
[TBL] [Abstract][Full Text] [Related]
11. The telomeric PARP, tankyrases, as targets for cancer therapy.
Seimiya H
Br J Cancer; 2006 Feb; 94(3):341-5. PubMed ID: 16421589
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
Tárkányi I; Aradi J
Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
[TBL] [Abstract][Full Text] [Related]
13. Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro.
Kelleher C; Kurth I; Lingner J
Mol Cell Biol; 2005 Jan; 25(2):808-18. PubMed ID: 15632080
[TBL] [Abstract][Full Text] [Related]
14. 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells.
Yatabe N; Kyo S; Kondo S; Kanaya T; Wang Z; Maida Y; Takakura M; Nakamura M; Tanaka M; Inoue M
Cancer Gene Ther; 2002 Jul; 9(7):624-30. PubMed ID: 12082463
[TBL] [Abstract][Full Text] [Related]
15. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells.
Goldkorn A; Blackburn EH
Cancer Res; 2006 Jun; 66(11):5763-71. PubMed ID: 16740715
[TBL] [Abstract][Full Text] [Related]
16. Antisense human telomerase reverse transcriptase could partially reverse malignant phenotypes of gastric carcinoma cell line in vitro.
Yang SM; Fang DC; Yang JL; Chen L; Luo YH; Liang GP
Eur J Cancer Prev; 2008 Jun; 17(3):209-17. PubMed ID: 18414191
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based combination telomerase inhibition therapy.
Shay JW; Wright WE
Cancer Cell; 2005 Jan; 7(1):1-2. PubMed ID: 15652743
[TBL] [Abstract][Full Text] [Related]
18. Rapid blockade of telomerase activity and tumor cell growth by the DPL lipofection of ribbon antisense to hTR.
Bajpai AK; Park JH; Moon IJ; Kang H; Lee YH; Doh KO; Suh SI; Chang BC; Park JG
Oncogene; 2005 Sep; 24(43):6492-501. PubMed ID: 16170384
[TBL] [Abstract][Full Text] [Related]
19. Telomere maintenance as a target for drug discovery.
Sekaran V; Soares J; Jarstfer MB
J Med Chem; 2014 Feb; 57(3):521-38. PubMed ID: 24053596
[TBL] [Abstract][Full Text] [Related]
20. Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
Dominick PK; Keppler BR; Legassie JD; Moon IK; Jarstfer MB
Bioorg Med Chem Lett; 2004 Jul; 14(13):3467-71. PubMed ID: 15177454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
